Skip to contentZ
Zivo Bioscience, Inc.
Z
ZIVOZivo Bioscience, Inc. Q3 2025 · 10-Q
Revenue$65.63K$65.63K+108.3% vs Q3 2024 Net Income-$1.03M-$1.03MN/M vs Q3 2024 EPS Diluted-$0.27-$0.27N/M vs Q3 2024 Gross Profit$21,288+125.3% Operating Income
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Zivo Bioscience, Inc. · CIK 1101026 · Engraved from SEC EDGAR
Operating Cash Flowderived-$266,556N/M Margins · derivedGross margin32.4%+2.4 pt vs Q3 2024
Operating margin-1551.8%+5623.0 pt vs Q3 2024
Net margin-1574.2%+5627.7 pt vs Q3 2024
ended Sep 30, 2025 · filed Nov 14, 2025 · 45 d after period end